DK173382B1 - Hidtil ukendte heterokonjugater og bispecifikke antistoffer - Google Patents

Hidtil ukendte heterokonjugater og bispecifikke antistoffer Download PDF

Info

Publication number
DK173382B1
DK173382B1 DK198901594A DK159489A DK173382B1 DK 173382 B1 DK173382 B1 DK 173382B1 DK 198901594 A DK198901594 A DK 198901594A DK 159489 A DK159489 A DK 159489A DK 173382 B1 DK173382 B1 DK 173382B1
Authority
DK
Denmark
Prior art keywords
heteroconjugate
antigen
antibody
cells
reactive
Prior art date
Application number
DK198901594A
Other languages
Danish (da)
English (en)
Other versions
DK159489A (da
DK159489D0 (da
Inventor
Jeffrey A Ledbetter
Original Assignee
Oncogen
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oncogen filed Critical Oncogen
Publication of DK159489D0 publication Critical patent/DK159489D0/da
Publication of DK159489A publication Critical patent/DK159489A/da
Application granted granted Critical
Publication of DK173382B1 publication Critical patent/DK173382B1/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/42—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum viral
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2806—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2812—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2815—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD8
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/289—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD45
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Virology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Spinning Or Twisting Of Yarns (AREA)
  • Coating With Molten Metal (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
DK198901594A 1988-04-04 1989-04-03 Hidtil ukendte heterokonjugater og bispecifikke antistoffer DK173382B1 (da)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US17682588A 1988-04-04 1988-04-04
US17682588 1988-04-04
US27193488A 1988-11-14 1988-11-14
US27193488 1988-11-14

Publications (3)

Publication Number Publication Date
DK159489D0 DK159489D0 (da) 1989-04-03
DK159489A DK159489A (da) 1989-10-05
DK173382B1 true DK173382B1 (da) 2000-09-11

Family

ID=26872636

Family Applications (1)

Application Number Title Priority Date Filing Date
DK198901594A DK173382B1 (da) 1988-04-04 1989-04-03 Hidtil ukendte heterokonjugater og bispecifikke antistoffer

Country Status (20)

Country Link
EP (1) EP0336379B1 (ko)
JP (1) JP2613106B2 (ko)
KR (1) KR100205833B1 (ko)
CN (1) CN1058296C (ko)
AT (1) ATE133866T1 (ko)
AU (1) AU629204B2 (ko)
DE (1) DE68925593T2 (ko)
DK (1) DK173382B1 (ko)
ES (1) ES2083960T3 (ko)
FI (1) FI105320B (ko)
GR (1) GR3019224T3 (ko)
HU (1) HU213576B (ko)
IE (1) IE72187B1 (ko)
IL (1) IL89823A (ko)
MY (1) MY106592A (ko)
NO (1) NO178699C (ko)
NZ (1) NZ228560A (ko)
PT (1) PT90195B (ko)
YU (1) YU68589A (ko)
ZA (1) ZA892448B (ko)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5846799A (en) * 1988-06-14 1998-12-08 La Region Wallone Human myeloperoxidase and its therapeutic application
US5460961A (en) * 1988-06-14 1995-10-24 La Region Wallonne Human myeloperoxidase and its therapeutic application
US5681566A (en) * 1988-10-24 1997-10-28 3I Research Exploitation Limited Antibody conjugates with two or more covalently linked FC regions
US6685941B1 (en) 1988-11-23 2004-02-03 The Regents Of The University Of Michigan Methods of treating autoimmune disease via CTLA-4Ig
AU6290090A (en) * 1989-08-29 1991-04-08 University Of Southampton Bi-or trispecific (fab)3 or (fab)4 conjugates
US5378815A (en) * 1989-10-20 1995-01-03 National Research Council Canada Process for indirect targeted immunocytolysis
US6406696B1 (en) 1989-10-27 2002-06-18 Tolerance Therapeutics, Inc. Methods of stimulating the immune system with anti-CD3 antibodies
WO1991006319A1 (en) * 1989-10-27 1991-05-16 Arch Development Corporation Methods and compositions for promoting immunopotentiation
US5273743A (en) * 1990-03-09 1993-12-28 Hybritech Incorporated Trifunctional antibody-like compounds as a combined diagnostic and therapeutic agent
IL97459A0 (en) * 1990-03-09 1992-06-21 Hybritech Inc Trifunctional antibody-like compounds as a combined diagnostic and therapeutic agent
JPH05268986A (ja) * 1990-03-19 1993-10-19 Bristol Myers Squibb Co モノクローナル抗体及びリンパ球の活性法
GB9021679D0 (en) * 1990-10-05 1990-11-21 Gorman Scott David Antibody preparation
US6129916A (en) * 1991-04-19 2000-10-10 Tanox, Inc. Method of Increasing activation on proliferation of T cells using antibody-microbead conjugates
US6106835A (en) * 1991-04-19 2000-08-22 Tanox, Inc. Modified binding molecules specific for T or B lymphocytes and their use as in vivo immune modulators
US5872222A (en) * 1991-04-19 1999-02-16 Tanox Biosystems, Inc. Conjugates of polymers and antibodies specific for T lymphocytes, and their use as adjuvants
US6197298B1 (en) 1991-04-19 2001-03-06 Tanox, Inc. Modified binding molecules specific for T lymphocytes and their use as in vivo immune modulators in animals
CA2065658A1 (en) * 1991-04-19 1992-10-20 Tse-Wen Chang Conjugates of liposomes or microbeads and antibodies specific for t lymphocytes and their use in vivo immune modulators
IE922233A1 (en) * 1991-07-10 1993-01-13 Augusto C Ochoa Short-term anti-cd3 stimulation of lymphocytes to increase¹their in vivo activity
GB9206422D0 (en) 1992-03-24 1992-05-06 Bolt Sarah L Antibody preparation
DE69227623T2 (de) * 1992-04-10 1999-05-20 Erland Uppsala Hanas Verfahren zum Nachweis einer CMV-Infektion
US5635602A (en) * 1993-08-13 1997-06-03 The Regents Of The University Of California Design and synthesis of bispecific DNA-antibody conjugates
DE69528894T2 (de) 1994-05-02 2003-03-27 Bernd Groner Bifunktionelles protein, herstellung und verwendung
DE4421391C1 (de) * 1994-06-18 1995-11-30 Gsf Forschungszentrum Umwelt Verwendung von Antikörpern gegen T-Zellen zur verlängerten Immunsuppression
EP0945139A1 (en) * 1998-03-23 1999-09-29 Katholieke Universiteit Nijmegen Methods and means for the treatment of immune related diseases such as Graft vs. Host disease
EP1189635A4 (en) * 1999-06-17 2003-04-23 Univ Vermont AUTOLOGOUS ADOPTIVE IMMUNOTHERAPY WITH T-CELLS OR B-CELLS B WHICH HAVE BEEN SENSITIZED TO ANTIGENS-SPECIFIC
DE10034607A1 (de) * 2000-07-20 2002-02-07 Gundram Jung Multispezifisches Reagenz zur selektiven Stimulierung von Zelloberflächenrezeptoren
EP1439857B1 (en) * 2001-10-12 2009-02-25 Schering Corporation USE OF BISPECIFIC ANTIBODIES BINDING TO THE ACTIVATING RECEPTOR FcEpsilonRI AND TO THE INHIBITING RECEPTOR OX2Ra (CD200Ra) TO REGULATE IMMUNE RESPONSES
GB0305702D0 (en) * 2003-03-12 2003-04-16 Univ Birmingham Bispecific antibodies
US20230096030A1 (en) * 2020-02-13 2023-03-30 UCB Biopharma SRL Bispecific antibodies against cd9 and cd7
EP4378529A1 (en) * 2022-12-03 2024-06-05 Universitätsklinikum Hamburg-Eppendorf Antibody for use in a therapy involving effector cell engagement

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4381292A (en) * 1980-11-14 1983-04-26 The Board Of Trustees Of The Leland Stanford Jr. University Anti-human T-lymphocyte monoclonal antibody
EP0153871A3 (en) * 1984-03-01 1987-07-01 Centocor, Inc. Antibody enhancement of immunogenicity of antigen
EP0179872B1 (en) * 1984-04-23 1991-06-19 Boston Biomedical Research Institute, Inc. Bispecific antibody determinants
GB8605316D0 (en) * 1986-03-04 1986-04-09 Royal Free Hosp School Med Immunosuppression
WO1987006240A1 (en) * 1986-04-14 1987-10-22 The General Hospital Corporation Heterobifunctional antibodies and method of use
GB8626412D0 (en) * 1986-11-05 1986-12-03 Clark M R Antibodies
DE3850542T2 (de) * 1987-09-23 1994-11-24 Bristol Myers Squibb Co Antikörper-Heterokonjugate zur Töting von HIV-infizierten Zellen.

Also Published As

Publication number Publication date
FI891528A0 (fi) 1989-03-30
NO891375D0 (no) 1989-03-31
HU213576B (en) 1997-08-28
FI105320B (fi) 2000-07-31
KR890015751A (ko) 1989-11-25
DE68925593T2 (de) 1996-06-13
DK159489A (da) 1989-10-05
JPH01304356A (ja) 1989-12-07
NZ228560A (en) 1991-10-25
CN1058296C (zh) 2000-11-08
NO178699C (no) 1996-05-15
HUT51338A (en) 1990-04-28
ES2083960T3 (es) 1996-05-01
FI891528A (fi) 1989-10-05
EP0336379A3 (en) 1990-01-31
IL89823A0 (en) 1989-12-15
YU68589A (en) 1991-10-31
MY106592A (en) 1995-06-30
DK159489D0 (da) 1989-04-03
AU3242389A (en) 1989-10-05
PT90195B (pt) 1994-06-30
IE72187B1 (en) 1997-03-26
EP0336379A2 (en) 1989-10-11
NO178699B (no) 1996-02-05
GR3019224T3 (en) 1996-06-30
IE891054L (en) 1989-10-04
ATE133866T1 (de) 1996-02-15
NO891375L (no) 1989-10-05
CN1036988A (zh) 1989-11-08
DE68925593D1 (de) 1996-03-21
JP2613106B2 (ja) 1997-05-21
PT90195A (pt) 1989-11-10
ZA892448B (en) 1989-12-27
KR100205833B1 (ko) 1999-07-01
EP0336379B1 (en) 1996-02-07
AU629204B2 (en) 1992-10-01
IL89823A (en) 1994-07-31

Similar Documents

Publication Publication Date Title
DK173382B1 (da) Hidtil ukendte heterokonjugater og bispecifikke antistoffer
US6010902A (en) Antibody heteroconjugates and bispecific antibodies for use in regulation of lymphocyte activity
JP6884709B2 (ja) 操作された免疫細胞の選別／枯渇のための、ｍＡｂが推進するキメラ抗原受容体系
Lanier et al. Functional and biochemical analysis of CD16 antigen on natural killer cells and granulocytes.
US7144575B2 (en) Methods for selectively stimulating proliferation of T cells
JP4009618B2 (ja) Ｔ細胞の増殖を選択的に刺激する方法
US6887466B2 (en) Methods for selectively stimulating proliferation of T cells
US7175843B2 (en) Methods for selectively stimulating proliferation of T cells
JP5154949B2 (ja) ウイルス感染を治療するための組成物および方法
CA3110905A1 (en) Chimeric antigen receptors against multiple hla-g isoforms
NO337619B1 (no) Sammensetning for å øke effektiviteten til terapeutiske antistoffer ved anvendelse av NK-cellepotensierende sammensetninger
US20220064255A1 (en) Anti-tcr antibody molecules and uses thereof
De Jong et al. Regulation of T-cell differentiation by CD2 and CD28 accessory molecules.
Tian et al. HIV envelope-directed signaling aberrancies and cell death of CD4+ T cells in the absence of TCR co-stimulation
Van Lier et al. Studies on the monocyte dependence of T-cell proliferation induced by monoclonal antibodies directed against regions I and II of the CD2 antigen.
CN114369168B (zh) 包含dap12和共刺激信号分子信号域的嵌合受体及其使用方法
Hansson et al. MHC nonrestricted cytotoxic T cell clones with selective specificity from patients with transitional cell carcinoma (TCC) of the urinary bladder
EP4378953A1 (en) Cd229 targeting moiety for the tratment of cd229 positive cancer
AU765876B2 (en) Methods for selectively stimulating proliferation of T cells
Leeuwenberg Functional studies on monoclon antibodies directed against the
Leeuwenberg Functional studies on monoclonal antibodies directed against the T cell differentiation antigens CD3 and CD7
Bishoff Natural killer lymphocyte membrane antigens involved in allorecognition
Forman et al. Immune Privilege and Tolerance–Therapeutic Antibody Approaches
Rosenzweig Immune Privilege and Tolerance-Therapeutic Antibody Approaches
DD295312A5 (de) Verfahren zur diagnostizierung eines defektes in der cd-rezeptorfunktion von patienten, welche an einer krankheit leiden, die eine t-zellen-fehlregulation oder funktionsstoerung beinhaltet

Legal Events

Date Code Title Description
PBP Patent lapsed

Country of ref document: DK